Clinical Trial

Early Identification of Brain Lesions in Multiple Sclerosis With Phase Sensitive Inversion Recovery MRI

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 18, 2025 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to compare the diagnostic accuracy of Phase-Sensitive Inversion Recovery (PSIR) MRI versus conventional T2-weighted (T2W) and Fluid Attenuated Inversion Recovery (FLAIR) sequences in detecting early brain lesions in patients with Multiple Sclerosis (MS). The study will include male and female participants aged 15-65 years diagnosed with MS per the 2017 McDonald criteria. This study hypothesizes that: * PSIR MRI will detect a significantly higher number of cortical lesions (intracortical, leukocortical, and juxtacortical) compared to conventional T2W and FLAIR sequences in MS patients (p \< 0.05). * Lesions identified exclusively by PSIR will correlate more strongly with clinical measures (EDSS disability scores and SDMT cognitive performance) than those detected by T2W/FLAIR alone, suggesting PSIR's superior sensitivity to clinically relevant pathology.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-25.
Trial Details
NCT Number NCT06955832
Lead Sponsor Benha University
Conditions Multiple Sclerosis
Enrollment 30 participants
Start Date 2025-06
Primary Completion 2025-06 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-05-18